Publications

Publications

  1. Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, Booth CM (2014) Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: A population-based study. Int J Urol. doi: 10.1111/iju.12611. Online
  2. Wang DH, Tiwari A, Kim ME, Clemons NJ, Regmi NL, Hodges WA, Berman DM, Montgomery EA, Watkins DN, Zhang X, Zhang Q, Jie C, Spechler SJ, Souza RF (2014) Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett’s metaplasia. J Clin Invest, 124(9): 3767-80. doi: 10.1172/JCI66603. Online
  3. Booth CM, Siemens DR, Wei X, Peng Y, Berman DM, Mackillop WJ (2014) Pathologic Factors Associated with Survival Benefit From Adjuvant Chemotherapy: A Population-Based Study of Bladder Cancer. BJU Int. doi: 10.1111/bju.12913. Online
  4. Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O’Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE (2014) Identification of ALK gene alterations in urothelial carcinoma. PLoS One 9(8):e103325. doi: 10.1371/journal.pone.0103325. Online
  5. Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL,Berman DM, Nifong TP, Blume-Jensen P (2014) Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Sci. 12:40. doi: 10.1186/1477-5956-12-40. Online
  6. Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P (2014) Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer, 111: 1201-1212. doi:10.1038/bjc.2014.396. Online
  7. Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM (2014) PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol. 2014 Jul 4. doi: 10.1038/modpathol.2014.85. Online
  8. Carvalho FLF, Simons BW, Eberhart CG and Berman DM (2014), Notch signaling in prostate cancer: A moving target. Prostate, 74: 933–945. doi: 10.1002/pros.22811. Online
  9. Booth CM, Siemens DR, Li G, Peng Y, Tannock IF, Kong W, Berman DM, and Mackillop, WJ (2014) Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-Based Outcomes Study. Cancer doi: 10.1002/cncr.28510. Online.
  10. Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial E, Weir B, Stack E, Park R, O’Brien R, Schultz F, Choueiri T, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia D, Chekaluk Y, Kwiatkowski K, Bochner B, Hahn W, Ligon A, Barletta J, Loda M, Berman DM, Kantoff P, Michor F, and Rosenberg JE (2014) Integrative analysis of 1q23.3 copy number gain in metastatic urothelial carcinoma. Clinical Cancer Research doi: 10.1158/1078-0432.CCR-13-0759. Online.
  11. Berman DM and Epstein JI (2014) When is prostate cancer really cancer? Urologic Clinics of North America doi:10.1016/j.ucl.2014.01.006. Online.
  12. Guancial EA, Bellmunt J, Roseberg JE, and Berman DM (2014) The Evolving Understanding of MicroRNA in Bladder Cancer. Urologic Oncology: Seminars and Original Investigations 32(1):41.e31–41.e40. Online
  13. Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan R, Pook D, Berman DM, Australian Prostate Cancer BioResource, Taylor RA, and Risbridger GP (2013) A pre-clinical xenograft model identifies castration-tolerant cancer repopulating cells in localized prostate tumors. Science Translational Medicine 5:187. Online
  14. Carvalho LF, Simons BW, Antonarakis ES, Rasheed Z, Douglas N, Villegas D, Matsui W, and Berman DM (2013) Tumorigenic potential of circulating prostate tumor cells. Oncotarget 4:413-21. PubMed
  15. Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, Schaeffer EM (2012) Wnt signaling though beta-catenin is required for prostate lineage specification. Dev Biol. 371:246-55. PubMed
  16. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe, SB, Miller, RM, Erho NG, Vergara IS, Ghadessi M, Huang Z, Gurel B, Park B, Davicioni E, Jenkins RB, Platz EA, Berman DM, and Schaeffer EM (2012) Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A 109:14977-82. PubMed
  17. Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM (2012) Sox9 is required for prostate development and prostate cancer initiation. Oncotarget 3(6):651-63. PubMed
  18. Berman DM, Bosenberg M, Orwant RL, Thurberg BL, Draetta G, Fletcher CD, and Loda M (2012) Investigative Pathology: Leading the Post-Genomic Revolution. Laboratory Investigation 92:4-8. PubMed
  19. Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM, Lotan TL (2011) PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 360:329-42. PubMed
  20. Toivanen R, Berman DM, Wang H, Pedersen J, Frydenberg P, Meeker AK, Ellem SJ, Risbridger GP and Taylor RA (2011) A bioassay to identify primary human prostate cancer repopulating cells. Stem Cells 29:1310. PubMed
  21. Ling S, Chang X, Schultz L, Lee TK, Chaux A, Marchionni L, Netto GJ, Sidransky D, and Berman DM (2011). An EGFR-ERK1/2-Sox9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res 71:3812. PubMed
  22. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM, Schaeffer EM (2011) Gene expression pathways of high grade localized prostate cancer. The Prostate 71(14):1568–1577. PubMed
  23. Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, Pandiyan K, Briggs KJ, Zhang W, Argani P, Simons B, Yu W, Matsui W, Van Criekinge W, Rassool FV, Zambidis E, Schuebel KE, Cope L, Yen J, Mohammad HP, Cheng L, Baylin SB (2010) Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res 70:7662. PubMed
  24. Rasheed Z, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV,  He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, and Matsui W (2010) Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102:340. PubMed
  25. Altiok S, Mezzadra H, Jagannath S, Tsottles N, Rudek MA, Abdallah N, Berman D, Forastiere A, Gibson MK (2010) A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. Int J Oncol 36:19. PubMed
  26. Brandt WD, Matsui W, Rosenberg JE, He X, Ling S, Schaeffer EM, and Berman DM (2009) Urothelial carcinoma: Stem cells on the edge. Cancer and Metastasis Reviews 28:291. PubMed
  27. Xiaobing He, Luigi Marchionni, Donna E. Hansel, Wayne Yu, Akshay Sood, Jie Yang, Giovanni Parmigiani, William Matsui, DM Berman (2009) Differentiation of a Highly Tumorigenic Basal Cell Compartment in Urothelial Carcinoma. Stem Cells 27:1487-95. PubMed
  28. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, Parmigiani G, Berman DM (2008) Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 27:7180-91. PubMed
  29. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, Berman DM (2007) Roles for the stem cell associated intermediate filament nestin in prostate cancer migration and metastasis. Cancer Research 67:9199-206. PubMed
  30. Zahurak M, Parmigiani G, Yu W, Scharpf RB, Berman D, Schaeffer E, Shabbeer S, Cope L (2007) Pre-processing Agilent microarray data. BMC Bioinformatics 8:142. PubMed
  31. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried TM, Lazebnik YA (2007) virus causes cancer by inducing massive chromosomal instability through cell fusion. Current Biology 17:431-7. PubMed
  32. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, Baylin SB (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genetics 39:237-42. PubMed
  33. Parwani AV, Berman DM, Burger PC, and Ali SZ (2004) Gliosarcoma: Cytopathologic characteristics on fine-needle aspiration (FNA) and Intraoperative touch imprint. Diagnostic Cytopathology 30:77-81. PubMed
  34. Berman DM, Desai N, Wang X, Karhadkar SS, Reynon M, Abate-Shen C, Beachy PA, and Shen MM (2004) Roles for Hedgehog signaling in androgen production and prostate ductal morphogenesis. Developmental Biology 7:387-398. PubMed
  35. Beachy PA, Karhadkar SS, and Berman DM (2004) Mending and Malignancy.  Nature 431:402. PubMed
  36. Karhadkar SS, Bova GB, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, and Beachy PA (2004) Hedgehog Signaling in prostate regeneration, neoplasia and metastasis. Nature 431:707-712. PubMed
  37. Beachy PA, Karhadkar SS. and Berman DM (2004) Tissue repair and stem cell renewal in carcinogenesis. Nature 432:324-331. PubMed
  38. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, and Baylin SB (2003) Hedgehog signalling within airway epithelial progenitors and in small cell lung cancer. Nature 422:313-317. PubMed
  39. Watkins DN, Berman DM, Baylin SB (2003) Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2:196-198. PubMed
  40. Berman DM, Karhadkar SS, Maitra AM, Montes de Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, and Beachy PA (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846-851. PubMed
  41. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA (2002) Medulloblastoma growth inhibition by Hedgehog pathway blockade. Science 297:1559-1561. PubMed
  42. Berman DM, Yang J, Epstein JI (2000) Foamy gland high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 24: 140-144. PubMed
  43. Silverman IE, Berman DM, Dike GL, Sung GY, Litt B, Wityk RJ (2000) Vertebrobasilar dolichoectasia associated with Marfan syndrome. J Stroke & Cerebrovasc Dis 9:196-198. PubMed
  44. Berman DM, Tian H, Russell DW (1995) Expression and regulation of steroid 5 alpha-reductase in the urogenital tract of the fetal rat. Mol. Endocrinol 9:1561-1570. PubMed
  45. Berman DM, Russell DW (1993) Cell-type-specific expression of rat steroid 5 alpha-reductase isozymes. Proc Natl Acad Sci USA 90:9359-9363. PubMed
  46. Andersson S, Berman DM, Jenkins EP, Russell DW (1991) Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 354:159-161. PubMed
  47. Jenkins EP, Hsieh CL, Milatovich A, Normington K, Berman DM, Francke U, Russell DW (1991) Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 11:1102-1112. PubMed

 

David M. Berman, MD, PhD, Professor
Department of Pathology and Molecular Medicine
Division of Cancer Biology and Genetics
Cancer Research Institute
Queen's University
Adjunct Faculty, Departments of Pathology, Oncology, and Urology
The Johns Hopkins Medical Institutions

Mailing address:
18 Stuart St., 329 Botterell Hall
Kingston, ON K7L 3N6

Telephones:
Office: 613-533-6000 ext 75218
Mobile: 613-329-1410

bermanlab.org

@Virchow on Twitter